Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work

Share Article

ImmuID, an alliance of three Washington (State) based companies (Pharmefex, Sync.MD, X-CELLSYSTEM), has appointed Linda S. Barnes, founder and Chief Executive Officer of X-CELLSYTEM, and Ali R. Siahpush, Ph.D., President and Founder of Pharmefex, as members of the alliance’s executive board.

News Image
“We’re delighted to welcome Linda S. Barnes and Ali R. Siahpush, Ph.D. as members of ImmuID’s executive board, and look forward to leveraging their industry expertise in helping people return to work and re-engage our economy safely, quickly and efficiently.”

ImmuID, an alliance of Pharmefex, Sync.MD, and X-CELLSYSTEM, is pleased to announce the appointment of Linda S. Barnes and Ali R. Siahpush, Ph.D. as members of the alliance’s executive board.

Based in the State of Washington, the fast-growing health alliance has designed an integrated and comprehensive end-to-end system to manage the massive task of getting Americans safely and responsibly back to work following the COVID-19 pandemic.

ImmuID accelerates the speed at which large numbers of employees can be tested. The alliance’s systematic risk-based approach, which includes a daily symptom tracker, as well as a convenient platform for testing employees, is especially designed to avoid a resurgence of COVID-19 cases until a vaccine against the SARS-CoV-2, the virus that causes COVID-19, may be available to protect employees.

With more than 25 years of experience in complex healthcare delivery operations, Linda S. Barnes, founder and Chief Executive Officer of X-CELLSYTEM, has an extensive background in cell therapies, blood services, public health research, quality assurance and regulatory affairs pertaining to blood and transfusion services and tissues.

“I’m excited to be part of this unique alliance of forward-thinking companies and be among the first few organizations in the nation to design a comprehensive and tested end-to-end system of getting people back to work and monitoring risk ongoing,” Linda S. Barnes said.

“Employers are grappling with a systematic approach for workforce management that offers flexibility, adaptability, monitoring, and compliance. ImmuID’s approach is a first step in effectively mitigating safety issues as employers bring their valued employees back to work and mitigate the unnecessary spread of the SARS-CoV-2 virus,” Barnes added.

With over 27 years’ experience in cell therapy and biologics development and commercialization, Ali R. Siahpush, Ph.D., President and Founder of Pharmefex, has advised numerous cell and gene therapy clients on a vast array of CMC topics. Before founding Pharmefex, Siahpush was Vice President of Product Development and Manufacturing Science at Dendreon. Prior to joining Dendreon, he spent nearly 20 years at Amgen in a number of capacities culminating as Executive Director of global process development.  

"I’m proud to play a role in helping our nation to re-emerge safely, quickly, and efficiently from the COVID-19 pandemic and the economic crisis it has caused,” Ali R. Siahpush noted.

“ImmuID’s approach ensures that Americans have the safest transition back to work and reopen our economy,” Siahpush added.

“We’re delighted to welcome Linda and Ali to our executive team and look forward to leveraging their industry expertise as we establish new partnerships with employers around the country. With their successful track record, we know that Linda and Ali will make an immediate impact in helping people return to work and re-engage our economy safely, quickly, and efficiently,” said Eugene Luskin, the Chief Executive Officer of Sync.MD and a member of ImmuID’s executive board.

About ImmuID
Founded in 2020, ImmuID is an alliance of three Washington (State) based companies, Pharmefex, Sync.MD and X-CELLSYSTEM. The alliance’s unique and systematic approach helps employers to manage and minimize the risk of returning their employees back to work. ImmuID also provides employees with confidence that proactive and timely measures are being taken to protect them from the risk of becoming infected with the SARS-CoV-2, the virus that causes COVID-19.

The alliance unique, adaptive and proprietary system includes a risk assessment algorithm based on twenty-five years of public health experience in assuring the safety of donated blood, approved, state-of-the-art tests for detection of SARS-CoV-2 antibodies and virus, and a secure, HIPAA-compliant, user-friendly, platform for storing and sharing test results. For further information, visit

About Sync.MD
Sync.MD patented technology enables individuals to securely store their complete and current health care records, and update information on their smartphone for seamless sharing of medical records with healthcare providers. Sync.MD helps solve the problem of connecting otherwise incompatible medical records systems, as well as meet the specific needs of those who travel or require specialized care beyond their usual healthcare provider. The company’s innovative technology enables higher quality of care, which means better outcomes and reduced costs for patients. For further information, visit

About Pharmefex
Founded in 2014 in Bellevue Washington, Pharmefex Consulting provides expert technical, regulatory, and compliance services to clients around the world.  Through a multidisciplinary approach, Pharmefex helps organizations to streamline product development, accelerate time to market, reduce the cost of goods, and prevent and resolve compliance problems for recombinant proteins and cellular immunotherapy products.  The company deploys decades of experience to deliver top-quality results for a diverse base of global clients, including pharmaceutical and biotechnology companies and the law firms that serve them. For further information, visit

About X-CellSystem
X-CellSystem provides a comprehensive and cost-effective system linking supply and demand for the cell therapy industry. Through technology and consultation, X-CellSystem accelerates access to advanced therapies. The company works with the international life sciences sector to source, qualify, and streamline research and commercialization of cell-based therapies to facilitate treatments for patients in need. Solutions include X-actID to improve the chain of identity of donor cells, form automation systems for early-stage biopharma, and multi-disciplinary approaches for cell sourcing, site qualification, and donor management. For further information, visit and follow @xcellsystem.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cecilia Zapata-Harms
(206) 602-3541
Email >
Visit website